If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Overall, the available evidence suggests that laser-based techniques are a minimally invasive treatment option for pilonidal disease with favorable short-term outcomes, while long-term outcomes remain to be further evaluated, necessitating long-term studies to assess its effectiveness as a first-line treatment.
=== Border fortification === In a report published in November 2022, the NGO Human Rights Watch found a marked increase in border fortification in a 7.4 kilometres (4.6 mi) long section of the border around Hoeryong. A HRW staff said that the COVID-19 pandemic had been a pretext in building new fences, guard posts and other infrastructure. Fortifications along wider stretches of the border were reported by Reuters in May 2023.
Dr. Reddy's originally launched in 1984 producing active pharmaceutical ingredients. In 1986, Reddy's started operations on branded formulations. Within a year Reddy's had launched Norilet, the company's first recognised brand in India. Soon, Dr. Reddy's obtained another success with Omez, its branded omeprazole – gastrointestinal ulcer and reflux oesophagitis medication – launched at half the price of other brands on the Indian market at that time. Within a year, Reddy's became the first Indian company to export the active ingredients for pharmaceuticals to Europe. In 1987, Reddy's started to transform itself from a supplier of pharmaceutical ingredients to other manufacturers into a manufacturer of pharmaceutical products. In 1999, Dr. Reddy's joined the Indian Pharmaceutical Alliance as a founding member in an effort to promote the development of generic drugs in India.
=== Reorganization after 1949 === Following the Communist party took over Chengdu in 1949, the institution underwent several reorganizations and name changes. In 1951, West China Union University was renamed West China University. In 1953, following the nationwide restructuring of higher education, it became the Department of Stomatology and affiliated stomatological hospital of Sichuan Medical College. China's first dedicated oral and maxillofacial surgery ward was also established there in 1953. A Research Institute of Stomatology was established in 1958. In 1966, a purpose-built stomatological hospital building was completed, while postgraduate education expanded in the following decades. The institution became an authorized master's-degree training site in stomatology in 1978 and a doctoral-degree training site in 1981. In 1985, Sichuan Medical College was renamed the West China University of Medical Sciences, and the dental institution became its College of Stomatology and affiliated stomatological hospital. The hospital was recognized as a Grade-III, Class-A stomatological specialist hospital in 1997.
Sources: en.wikipedia.org
== See also == List of cutaneous conditions List of target antigens in pemphigoid List of immunofluorescence findings for autoimmune bullous conditions List of human leukocyte antigen alleles associated with cutaneous conditions
The therapeutic properties of alprazolam are similar to other benzodiazepines and include anxiolytic, anticonvulsant, muscle relaxant, hypnotic, and amnesic; however, it is used mainly as an anxiolytic. Giving alprazolam, as compared to lorazepam, has been demonstrated to elicit a statistically significant increase in extracellular dopamine D1 and D2 concentrations in the striatum.
Peukert saw his work as a "warning against the fallacious notion that the normality of industrial society is harmless" and urged historians to consider the "dark side of modernity", instead of seeing modernity as a benign development that was always for the best. Peukert wrote: "The view that National Socialism was...one of the pathological development forms of modernity does not imply that barbarism is the inevitable logical outcome of modernization. The point, rather, is that we should not analyse away the tensions between progressive and aberrant features by making a glib opposition between modernity and tradition: we should call attention to the rifts and danger-zones which result from the civilizing process itself, so that the opportunities for human emancipation which it simultaneously creates can be more thoroughly charted. The challenges of Nazism shows that the evolution to modernity is not a one-way trip to freedom. The struggle for freedom must always be resumed afresh, both in inquiry and in action". Peukert argued that though völkisch racism was extreme, it was by no means exceptional, and instead reflected the logic promoted by the social sciences throughout the West which had argued that the state can and should foster "normality" while identifying "the non-conformity that is to be segregated and eliminated". Seen in this perspective, for Peukert the genocide against the Jews and Romany were only part of a wider project to eliminate all unhealthy genes from the volksgemeinschaft.
A mendelian randomization trial in humans found that a 1-standard deviation increase in genetically proxied LDL-C levels was associated with 1.2 years lower lifespan. This presents with an interesting candidate for increasing life span in select populations with such potentially deleterious mutations, since atherosclerosis is one of the leading causes of mortality through causing potentially fatal atherosclerotic cardiovascular disease. Considering many LDL-C lowering drugs are already approved to reduce mortality in select populations, there is certainly not a paucity of research.
The corporate office has had a few locations, and previously maintained an office at 2516 Via Tejon in Palos Verdes, then at 2424 Moreton Street in Torrance before settling into Irvine (at 17901 Von Karman Avenue) in 1976.
Sources: en.wikipedia.org
Tarui disease (GSD-VII) patients do not experience the "second wind" phenomenon; instead are said to be "out-of-wind." However, they can achieve sub-maximal benefit from lipid metabolism of free fatty acids during aerobic activity following a warm-up.
The presentation of amyloidosis is broad and depends on the site of amyloid accumulation. The kidney and heart are the most common organs involved. Amyloid deposition in the kidney often involve the glomerular capillaries and mesangial regions, affecting the organ's ability to filter and excrete waste and retain plasma protein. This can lead to high levels of protein in the urine (proteinuria) and nephrotic syndrome. Several types of amyloidosis, including the AL and AA types, are associated with nephrotic syndrome. Approximately 20% and 40–60% of people with AL and AA amyloidosis respectively progress to end-stage kidney disease requiring dialysis.
Prior to founding the Center for Biomedical Mass Spectrometry at Boston University School of Medicine in 1994, Costello was a senior research scientist and the associate director of the National Institutes of Health Research Resource for Mass Spectrometry at Massachusetts Institute of Technology for 20 years. She is a William Fairfield Warren Distinguished Professor and the director of the Center for Biomedical Mass Spectrometry at the Boston University School of Medicine. Costello served as the president of the American Society for Mass Spectrometry (2002–2004), the Human Proteome Organization (2011–2012), and the International Mass Spectrometry Foundation (2014–2018). She currently serves on the board of directors of the US Human Proteome Organization, and the editorial board of Clinical Proteomics.
Some 238U atoms, however, could capture another amount of neutrons (most likely, 16 or 17). The discovery of fermium (Z = 100) required more material, as the yield was expected to be at least an order of magnitude lower than that of element 99, and so contaminated coral from the Enewetak atoll (where the test had taken place) was shipped to the University of California Radiation Laboratory in Berkeley, California, for processing and analysis. About two months after the test, a new component was isolated emitting high-energy α-particles (7.1 MeV) with a half-life of about a day. With such a short half-life, it could only arise from the β− decay of an isotope of einsteinium, and so had to be an isotope of the new element 100: it was quickly identified as 255Fm (t = 20.07(7) h). The discovery of the new elements, and the new data on neutron capture, was initially kept secret on the orders of the U.S. military until 1955 due to Cold War tensions. Nevertheless, the Berkeley team was able to prepare elements 99 and 100 by civilian means, through the neutron bombardment of plutonium-239, and published this work in 1954 with the disclaimer that it was not the first studies that had been carried out on the elements. The "Ivy Mike" studies were declassified and published in 1955. The Berkeley team had been worried that another group might discover lighter isotopes of element 100 through ion-bombardment techniques before they could publish their classified research, and this proved to be the case.
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.